Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction: The healing and early afterload reducing therapy trial

Circulation

Volumn 95, Issue 12, 1997, Pages 2643-2651

  Pfeffer, Marc A ^a   Greaves, Sally C ^a   Arnold, J Malcolm O ^b   Glynn, Robert J ^a   LaMotte, Frances S ^a   Lee, Richard T ^a   Menapace Jr , Francis J ^c   Rapaport, Elliot ^d   Ridker, Paul M ^a   Rouleau, Jean Lucien ^e   Solomon, Scott D ^a   Hennekens, Charles H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c GEISINGER MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Angiotensin converting enzyme inhibitor; Echocardiography; Myocardial infarction; Ventricular remodeling

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL;

ACUTE HEART INFARCTION; ADULT; AGED; ARTERIAL PRESSURE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; ENZYME INHIBITION; HEART AFTERLOAD; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WOUND HEALING;

EID: 17544390753     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.12.2643     Document Type: Article

References (40)

1. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarctcd left ventricle of the rat. Circ Res. 1985;57:84-95.
2. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation. 1985;72:406-412.
3. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on Behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial . N Engl J Med. 1992;327:669-667.
4. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
5. Gruppo Italiano per lo Studio della sopravvivenza Nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lanect. 1994;343:1115-1122.
6. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 1995;332:80-85.
7. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669-685.
8. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CC-1). Lancet. 1995;345:686-687.
9. Kober L, Torp-Pederson C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L,Pauly NC Aliot E, Persson S. Camm AJ. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670-1676.
10. Pfeffer MA. ACE inhibition in acute myocardial infarction. N Engl J Med. 1995;332:118-120. Editorial.
11. Ball SG, Hall AS. Who should be treated with angiotensin-converting enzyme inhibitors after myocardial infarction? Am Heart J. 1996;132:244-250.
12. Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H, on Behalf of the CONSENSUS II Study Group. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327:678-684.
13. Furberg CD, Campbell RW, Pitt B. ACE inhibitors after myocardial infarction. N Engl J Med. 1993;328:967-968; 968-969. Letter and discussion.
14. Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G, for the Meeting Participants. ACE inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials. Circulation. 1995;92:3132-3137.
15. Pfeffer MA, Hennekens CH, for the HEART Study Executive Committee. When a question has an answer: rationale for our early termination of the HEART trial. Am J Cardiol. 1995;75:1173-1175.
16. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Mové LA, Dagenais GR, Lamas GA, Klein M, Sussex B, Goldman S, Menapace FJ, Parker JO, Lewis S, Sestier F, Gordon DF, McEwan P, Bernstein V, Braunwald E, for the SAVE Investigators. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction: the protective effects of captopril. Circulation. 1994:89:68-75.
17. Schluchter MD. 5V: unbalanced repeated measures models with structured covariance matrices. In: Dixon WJ, ed. BMDP Statistical Software, Vol 2. Berkeley, Calif: University of California: 1990:1207-1244.
18. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Acute myocardial infarction: pre-hospital and in-hospital management. Eur Heart J. 1996;17:43-63.
19. Ryan TJ, Anderson JL, Antman EM. Braniff BA, Brooks NH, Califf RM. Hillis LD, Hiratzka LF, Rapaport E, Riegel BJ, Russell RO, Smith EE III, Weaver WD. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guideline (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996;28:1328-1428.
20. Smith SC, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, Gotto AM, Gould KL, Greenland P, Grundy SM, Hill MN, Hlatky MA, Houston-Miller N, Krauss RM, LaRosa J, Ockene IS, Oparil S, Pearson TA, Rapaport E, Starke RD, the Secondary Prevention Panel. Preventing heart attack and death in patients with coronary disease. Circulation. 1995;92:2-4.
21. Fallen EL, Cairns J, Dafoe W. Frasure-Smith N, Genest J, Massel D, Peretz D, Tremblay GJL, Williams WL. Management of the postmyocardial infarction patient: a consensus report: revision of 1991 CCS guidelines. Can J Cardiol. 1995;11:477-486.
22. Hennekens CH, Godfried SL, Albert CM, Gaziano JM, Buring JE. Adjunctive drug therapies during and post acute myocardial infarction. N Engl Med. 1996;335:1660-1667.
23. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med. 1988;319:80-86.
24. Sharpe N, Smith H, Murphy J, Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet. 1988;1:255-259.
25. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation. 1990:81:1161-1172.
26. Oldroyd KG, Pye MP, Ray SG, Christie J, Ford I, Cobbe SM, Dargie HJ. Effects of early captopril administration on infarct expansion, left ventricular remodeling and exercise capacity after acute myocardial infarction. Am J Cardiol. 1991;68:713-718.
27. Sharpe N, Smith H, Murphy J, Greaves S, Hart H, Gamble G. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet. 1991;337:872-876.
28. Foy SG, Crozier IG. Turner JG, Richards AM, Frampton CM, Nicholls MG, Ikram H. Comparison of enalapril versus captopril on left ventricular function and survival three months after acute myocardial infarction (the "PRACTICAL" study). Am J Cardiol. 1994;73:1180-1186.
29. Nabel EG, Topol EJ, Galeana A, Ellis SG, Bates ER, Werns SW, Wallon JA. Muller DW, Schwaiger M, Pitt B. A randomized placebo-controlled trial of combined early intravenous captopril and recombinant tissue-type plasminogen activator therapy in acute myocardial infarction. J Am Coll Cardiol. 1991;17:467-473.
30. Kingma JH, van Gilst WH, Peels KH, Dambrink JHE, Verheugt FW, Wielenga RP. Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction: results from the Captopril and Thrombolysis Study (CATS). Eur Heart J. 1994;15:898-907.
31. van Gilst WJ, Kingma JH, Heels KH, Dambrink JHE, St John Sutton M, on Behalf of the CATS Investigators. Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? Results of one-year serial echocardiographic follow-up from the Captopril and Thrombolysis Study (CATS). J Am Coll Cardiol. 1996;28:114-121.
32. GISSI-3 Investigators, M Negri Institute, and ANMCO I. Causes of early in-hospital mortality of patients with acute myocardial infarction: the impact of ACE-inhibitor treatment. Circulation. 1995;1-673. Abstract.
33. Schuster EH, Bulkley BH. Expansion of transmural myocardial infarction: a pathophysiologic factor in cardiac rupture. Circulation. 1979;60:1532-1538.
34. Linz W, Schoelkens BA, Ganten D. Converting enzyme inhibitor specifically prevents development and induces the regression of cardiac hypertrophy in rats. Clin Exp Hypertens. 1989;11:1325-1350.
35. Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation. 1982;66:1146-1149.
36. Bolli R. Myocardial "stunning" in man. Circulation. 1992;86:1671-1691.
37. Bourdillon PDV, Broderick TM, Williams ES, Davis C, Dillon JC, Armstrong WF, Fineberg N, Ryan T, Feigenbaum H. Early recovery of regional left ventricular function after reperfusion in acute myocardial infarction assessed by serial two-dimensional echocardiography. Am J Cardiol. 1989;63:641-646.
38. Solomon SD, Rayan ME, Finn PV, Pfeffer MA, Pfeffer JM. Early left ventricular function predicts subsequent ventricular remodeling following myocardial infarction in rats. J Am Coll Cardiol. 1996;27:365a. Abstract.
39. Lamas GA. Pfeffer MA. Increased left ventricular volume following myocardial infarction in man. Am Heart J. 1986;111:30-35.
40. Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction: potential mechanisms and early predictors. Circulation. 1993;87:755-763.